We Use Our Expertise to Develop Customized Strategies that are Implementation Ready
Creating a customized Drug Target Analysis requires a strong combination of both Intellectual Property (IP) and Food and Drug Administration (FDA) knowledge. Our firm is unique in that we have deep bench strength in both practices, with attorneys who collaborate for our Life Sciences clients on a daily basis. This rare combination allows for a comprehensive work product without the time and cost of obtaining analyses from two boutique firms.
From Brand Name and Generic Drug Companies to Investors, We Have You Covered
Whether your company has a brand name drug that is facing impending patent or market exclusivity expiration, you represent a generic drug company looking to introduce or acquire a product, or you are an investor in the space looking for an innovative product to help you break through the market – let our team do the heavy lifting for you.
Confident Recommendations Based on Comprehensive Research
Our Drug Target Analysis is tailored to your organization. Our Deep Dive Analysis includes multi-faceted looks at your portfolio against the broader landscape, identifies where vulnerabilities may lie, provides a summary of relevant clinical trials in the target drug’s product category, and more. On top of this, we arm you with an easy-to-digest Executive Summary, and a personalized Drug Target Analysis Report that combines our insights and analysis directed to your business goals.
And, we don’t stop there. If you choose to move forward, we will assist you with all aspects of the drug approval process, patent prosecution and litigation, due diligence and FDA strategies.
Our Cross-Section Team Collaborates to Bring Nuanced Insights
To conduct a customized analysis of this depth and acuity requires a strong, seamless blend of IP and FDA prowess. Our patent and FDA lawyers collaborate on a daily basis, working together to serve clients under our multi-practice Life Sciences umbrella.
Our dedicated FDA practice understands both the business and the science of developing and marketing FDA-regulated products. Our relationships and experience working with the FDA can be paramount to a drug company’s success. Few firms can match the level of knowledge, scientific understanding and FDA experience we offer, including having a team member who was the former FDA associate chief legal counsel and a team member who previously served as director of the FDA’s Office of Criminal Investigations. In addition, we have appeared before most of FDA’s drug-reviewing divisions within the Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER).
Our Life Sciences IP team has extensive experience in patent-portfolio development, strategic patent prosecution and patent litigation, and counseling clients on potential FDA implications of their patent strategy. Our team includes pharmaceutical patent lawyers who have worked at the United States Patent and Trademark Office (USPTO), as well as individuals who have worked within FDA’s Office of Generic Drugs.
